Key Metrics
Factor Lens
Seasonal Performance
Dividends
Per-share amounts adjusted for stock splits.
Last 12 Payouts
| Period | Ex-Date | Amount / Share |
|---|---|---|
| Q3 2026 | ~2026-03-31 | $0.0800 |
| Q2 2025 | ~2025-12-31 | $0.0800 |
| Q1 2025 | ~2025-09-30 | $0.0800 |
| Q4 2024 | ~2025-04-01 | $0.0800 |
| Q3 2025 | ~2025-03-31 | $0.0800 |
| Q2 2024 | ~2024-12-31 | $0.0800 |
| Q1 2024 | ~2024-09-30 | $0.0800 |
| Q3 2024 | ~2024-03-31 | $0.0800 |
| Q2 2023 | ~2023-12-31 | $0.0800 |
| Q1 2023 | ~2023-09-30 | $0.0800 |
| Q3 2023 | ~2023-03-31 | $0.0800 |
| Q2 2022 | ~2022-12-31 | $0.0800 |
Financial Trends
Revenue & Net Income
Earnings Per Share
Margins
Cash Flow
Company Overview
Bio-Techne Corporation develops, manufactures and sells life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. The… Company operates in two segments: Protein Sciences and Diagnostics and Spatial Biology. The Protein Sciences segment, representing approximately 72% of net sales, includes the Reagent Solutions division providing specialized proteins such as cytokines, growth factors, antibodies, small molecules, tissue culture sera and cell selection technologies for research and therapeutic development, and the Analytical Solutions division offering manual and automated protein analysis instruments and immunoassays. Key brands include R&D Systems, Tocris Biosciences, Novus Biologicals and ProteinSimple. The Diagnostics and Spatial Biology segment, representing approximately 28% of net revenues, includes the Spatial Biology division providing in-situ hybridization assays and spatial genomic analysis instruments, the Molecular Diagnostics division offering exosome-based liquid biopsy techniques and genetic/oncology kits, and the Diagnostic Reagents division providing calibrators, controls and diagnostic assays for the regulated diagnostics market. The Company serves researchers in academia and industry, pharmaceutical and biotech companies, contract research organizations, diagnostic and therapeutic customers, and clinical laboratories globally through direct sales and distribution partnerships.
- Name
- Bio-Techne Corporation
- Industry
- Biotechnology
- CEO
- Kim Kelderman · President and Chief Executive Officer
- Employees
- 3,800 as of 2025-06-30
- IPO Date
- 2006-10-27
- Phone
- (612) 379-8854
- Address
- 614 McKinley Place N.E., Minneapolis, MN 55413
- Website
- http://www.biotechne.com
Key Executives
| Name | Title | FY Pay |
|---|---|---|
| Amy E. Herr | Director (Board Member) | — |
| John L. Higgins | Director (Board Member) | — |
| Robert V. Baumgartner | Independent Chair of the Board | — |
| Julie L. Bushman | Director (Board Member) | — |
| Kim Kelderman | President and Chief Executive Officer | — |
Latest News
- 2026-04-21
- 2026-04-17
- 2026-04-16
- 2026-04-15
- 2026-04-14
- 2026-04-13
- 2026-04-13
- 2026-04-10